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Abstract 
Acute right ventricular (RV) failure is a complex clinical syndrome that results from many causes. Research efforts 
have disproportionately focused on the failing left ventricle, but recently the need has been recognized to achieve a 
more comprehensive understanding of RV anatomy, physiology, and pathophysiology, and of management 
approaches. Right ventricular mechanics and function are altered in the setting of either pressure overload or volume 
overload. Failure may also result from a primary reduction of myocardial contractility owing to ischaemia, 
cardiomyopathy, or arrhythmia. Dysfunction leads to impaired RV filling and increased right atrial pressures. As 
dysfunction progresses to overt RV failure, the RV chamber becomes more spherical and tricuspid regurgitation is 
aggravated, a cascade leading to increasing venous congestion. Ventricular interdependence results in impaired left 
ventricular filling, a decrease in left ventricular stroke volume, and ultimately low cardiac output and cardiogenic 
shock. Identification and treatment of the underlying cause of RV failure, such as acute pulmonary embolism, acute 
respiratory distress syndrome, acute decompensation of chronic pulmonary hypertension, RV infarction, or 
arrhythmia, is the primary management strategy. Judicious fluid management, use of inotropes and vasopressors, 
assist devices, and a strategy focusing on RV protection for mechanical ventilation if required all play a role in the 
clinical care of these patients. Future research should aim to address the remaining areas of uncertainty which result 
from the complexity of RV haemodynamics and lack of conclusive evidence regarding RV‐specific treatment 
approaches. 
Keywords: Right ventricular dysfunction; Right ventricular function; Heart failure; Intensive care; Cardiogenic 
shock 
Introduction 
Acute right ventricular (RV) failure can be defined as a rapidly progressive syndrome with systemic 
congestion resulting from impaired RV filling and/or reduced RV flow output. Most often it is associated 
with increased RV afterload or preload and consequent RV chamber dilatation and tricuspid regurgitation 
(Figure 1).
1, 2
 The prevalence of acute RV failure is difficult to estimate, but its predominant causes [i.e. 
left‐sided heart failure, acute pulmonary embolism (PE), acute myocardial ischaemia] are common.3-5 It is 
observed in 3–9% of acute heart failure admissions, and the in‐hospital mortality of patients with acute 
RV failure ranges from 5 to 17%.
6-10 
 
Research efforts have disproportionately focused on the failing left ventricle, but recently more 
attention has been placed on understanding RV anatomy, physiology, dysfunction, and management.
11
 
Right ventricular failure is a heterogeneous syndrome, and its varied aetiologies require individualized 
treatment. Recognizing the numerous aspects of RV failure, the Heart Failure Association (HFA) and the 
Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of 
Cardiology (ESC) convened a multidisciplinary group of experts to discuss state‐of‐the‐art principles 
pertaining to RV failure and its aetiology, clinical presentation, assessment, treatment, and areas where 
focused research is needed. This paper summarizes the dialogue and suggests priorities for research in 
this field. 
 
 
  
 
 
 
Figure 1. Pathophysiology of acute right ventricular failure. LV, left ventricular; RV, right ventricular. 
Pathophysiology 
Anatomy and mechanics of right ventricular function 
The thin‐walled right ventricle pumps the entire systemic venous return into the pulmonary circulation 
for gas exchange. Right ventricular function integrates preload, afterload, contractility, pericardial 
constraint, interaction with the left ventricle, and cardiac rhythm.
12-14
 Venous return depends on the 
pressure gradient between the peripheral vasculature where the mean systemic filling pressure (although 
not well characterized in humans) is approximately 7–10 mmHg, and the right atrial (or central venous) 
pressure, which is usually 0 mmHg at rest.15 In contrast to the left ventricle, twisting and rotational 
movements do not contribute significantly to RV contraction. Instead, the most important mechanisms are 
the bellows‐like inward movement of the free wall, the contraction of the longitudinal fibres drawing the 
tricuspid annulus toward the apex, and the traction on the free wall as a result of left ventricular 
contraction. The contraction of the right ventricle is sequential, starting with the trabeculated myocardium 
and ending with the contraction of the infundibulum (25–50 ms delay).16 Because RV afterload is very 
low under normal conditions, blood flows from the RV into the pulmonary circulation both during systole 
and during the early part of diastole, leading to the absence of isovolumetric relaxation.
15
 
Aetiology and pathogenesis of right ventricular failure 
Right ventricular mechanics and function are altered in the setting of either pressure overload or 
volume overload (Figure 1, Table 1). Failure may also result from a primary reduction of myocardial 
contractility owing to ischaemia, cardiomyopathy, or arrhythmia.  
  
Table 1. Causes and differential diagnosis of acute right ventricular failure  
 
Acute left ventricular failure 
Right ventricular ischaemia/infarction 
Acute pulmonary embolism 
Exacerbation of chronic lung disease and/or hypoxia 
Acute lung injury or respiratory distress syndrome 
Sepsis 
Chronic pulmonary hypertension (groups 1–5) 
Pericardial disease (tamponade) 
Arrhythmias (supraventricular or ventricular tachycardia) 
Congenital heart disease (e.g. atrial or ventricular septal defect, Ebstein's anomaly) 
Valvulopathies (e.g. tricuspid valve regurgitation, pulmonary valve stenosis) 
Cardiomyopathies (e.g. arrhythmogenic right ventricular dysplasia, familial, idiopathic) 
Myocarditis or other inflammatory diseases 
Cardiac surgery (e.g. cardiac transplant or left ventricular assist device implantation) 
Haematological disorders (e.g. acute chest syndrome in sickle cell disease) 
 
 
The right ventricle is not built to handle large or rapid increases in pulmonary artery pressure. 
However, it possesses, like the left ventricle, the capacity to adapt its systolic function to preserve 
ventriculo‐arterial coupling. During the acute response, the right ventricle uses a homeometric or systolic 
functional adaptation (Anrep's law of the heart) within minutes of a rise in pulmonary artery pressure; 
chronically it implements a heterometric or dimensional adaptation (Starling's law of the heart) to 
preserve flow output. Insufficient systolic functional adaptation will limit cardiac output and ultimately 
result in systemic hypotension and cardiogenic shock; dilatation with eventual diastolic dysfunction 
causes systemic congestion. 
 
Dyssynchrony, or inhomogeneous regional contraction, occurs early in the adaptation of the right 
ventricle to increased systolic function demands. Asynchrony, or delayed RV systole (i.e. the right 
ventricle is still ejecting blood while the left ventricle is already filling), appears when the right ventricle 
dilates and the septum shifts. At this stage, the left ventricle becomes underfilled, with resultant 
hypotension and altered systolic ventricular interactions. 
 
Systolic or diastolic ventricular interdependence relates to the concept that the functioning of the left 
ventricle affects the functioning of the right ventricle and vice versa (Figure 2). The main anatomical 
determinants of ventricular interdependence include the interventricular septum, the pericardium, and the 
continuity between myocardial fibres of the left and right ventricle.
16 
Some (up to 40%) of the RV 
contractile force originates from left ventricular contraction.
17 
Moreover, when the right ventricle dilates 
acutely, the interventricular septum is shifted leftward, both in systole and diastole as both ventricles 
‘compete’ for space within the pericardium. Notably, this shift occurs only in diastole when ventricular 
pressures are low. Septal shift compresses the left ventricle, impairs its filling, and leads to reduced left 
ventricular contractility (see the Supplementary material online, Cases S1, S2).
12, 13
 By the same 
mechanism, acute RV dilatation also leads to increased pericardial constraint, which in turn decreases the 
distensibility of the left ventricle and reduces left ventricular filling (preload), ultimately leading to a drop 
in stroke volume.
1, 13
 
  
 
 
 
Figure 2. Ventricular interdependence in right ventricular failure. Dilatation of the right ventricle shifts the interventricular septum 
toward the left, changing left ventricular geometry. Acute right ventricular distension may also lead to an increase in pericardial 
constraint (arrows). These changes may contribute to low cardiac output state by decreasing left ventricular distensibility, preload, 
and ventricular elastance. Reprinted with permission from Haddad F, Doyle R, Murphy DJ, Hunt SA. Right ventricular function in 
cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 
2008;117:1717–1731.  
Consequences of right ventricular failure 
The typical dilatation of the right ventricle in response to volume overload is shown in the 
Supplementary material online, Case S3. In the setting of acutely increased afterload, the right ventricle 
responds in a similar manner by increasing its end‐diastolic volume and contractility, but RV failure may 
occur rapidly if these mechanisms prove unable to generate sufficient pressure to maintain flow (e.g. past 
the thromboembolic obstruction in the case of acute PE) (see the Supplementary material online, Cases 
S4, S5).
1
 In chronically evolving pulmonary hypertension from precapillary or postcapillary causes, the 
right ventricle responds to increasing afterload with progressive hypertrophy, which allows it to maintain 
cardiac output at rest over long periods of time. The right ventricle finally dilates in end‐stage disease, 
leading to tricuspid regurgitation and, ultimately, decreased cardiac output (see the Supplementary 
material online, Cases S1, S2). Acute decompensations of chronic pulmonary hypertension may lead to a 
clinical presentation barely distinguishable from that of ‘truly’ acute RV failure as, for example, in acute 
pulmonary embolism.
1
 
 
Venous congestion commonly occurs in acute RV failure. Dysfunction leads to impaired RV filling 
and increased right atrial pressures.
1 
As RV dysfunction progresses to overt RV failure, the RV chamber 
becomes more spherical and tricuspid regurgitation is aggravated, leading to progressive venous 
congestion.
15, 18
 Venous congestion and increased central venous pressure also lead to impairment of 
renal, intestinal, and hepatic function,
19-26
 which are important predictors of poor prognosis in patients 
with acute RV failure
.22, 23, 26-28
 
  
Clinical presentation and assessment 
Initial triage: clinical assessment and biochemical markers 
The clinical presentation of acute RV failure varies depending on the underlying cause and presence 
of comorbidities (Table 2).
12, 17
 
Table 2. Clinical signs and biochemical markers of acute right ventricular (RV) failure 
Clinical signs Biochemical markers 
  
Hypoxaemia Increased lactate levels 
Signs of systemic congestion Elevated natriuretic peptides (BNP or NT‐proBNP) 
Jugular venous distension, hepatojugular reflux Elevated cardiac troponin I or T 
Peripheral oedema, pericardial effusion, congestive 
hepato/splenomegaly, ascites, anasarca*  
Abnormal liver biochemistry (e.g. elevated 
transaminases, bilirubin, prolonged prothrombin 
time) 
Signs of right ventricular dysfunction Abnormal renal function (blood urea nitrogen, 
creatinine) 
Third heart sound, systolic murmur of tricuspid regurgitation, hepatic 
pulse, signs of concomitant left ventricular dysfunction 
D‐dimer levels†  
Paradoxical pulse  
Signs of low cardiac output state  
Hypotension, tachycardia, cool extremities, central nervous system 
abnormalities, oliguria 
 
  
 
BNP, brain natriuretic peptide; NT‐proBNP, N‐terminal pro brain natriuretic peptide.  
* Particularly in acute decompensation of chronic RV failure.  
† D‐dimer testing is used in the diagnostic workup of suspected pulmonary embolism.  
The primary goal of pre‐hospital and emergency department triage is to assess the acuity and urgency 
of the clinical situation. The aetiology of RV failure should be sought (Table 1), and the diagnosis or 
exclusion of causes requiring specific treatment (such as PE) should be prioritized.  
 
The initial triage is based on clinical history and physical examination. The electrocardiogram, arterial 
blood gases, and blood lactate should also be assessed.
29
 Examples of typical electrocardiograms in 
different clinical settings are shown in the Supplementary ECG material online.  
 
On hospital admission, focused bedside echocardiography provides rapid information on cardiac 
structure and function (see section on Echocardiography). Chest X‐ray is routinely obtained and 
occasionally yields specific findings. 
 
There are currently no biomarkers specific for RV failure.
30 
Consequently, the clinical utility of B‐
type natriuretic peptides and cardiac troponin testing depends on the clinical context in which acute RV 
failure presents. These markers possess high sensitivity for the early detection of RV failure and 
myocardial injury, respectively, in patients with confirmed acute PE;
31-34
 they were also associated with 
poor prognosis in RV failure related to pulmonary arterial hypertension (PAH).
22, 35
 Novel biomarkers for 
detecting acute RV failure are under evaluation.
36-39
 
  
Echocardiographic assessment 
Bedside focused cardiac ultrasound in the emergency department or intensive/coronary care unit is a 
first‐line test in the assessment of RV size, function and load.40, 41 It can be used to exclude extrinsic 
causes of acute RV failure, especially those needing immediate treatment (such as pericardial tamponade 
which mimics acute RV failure), and to estimate right atrial pressure by assessing the diameter and the 
respiratory collapse of the inferior vena cava. The quantification of pulmonary artery systolic pressure by 
the trans‐tricuspid pressure gradient is a reliable method compared with invasive measurements.42 All 
available views of the right heart, including apical four‐chamber RV‐focused (see the Supplementary 
material online, Cases S1–S3) and subcostal views, should be used to estimate accurately RV 
enlargement, sphericity, and degree of RV dilation compared with left ventricular dilation.
42
 
 
The latest advances in ultrasound techniques are shifting from mostly qualitative assessment of global 
and segmental RV function in the past to quantitative evaluation.
43 
Recently updated recommendations 
from the American Society of Echocardiography and the European Association of Cardiovascular 
Imaging
44
 advocate quantitative assessment of global RV function by at least one of the following 
parameters: fractional area change (FAC; Supplementary material online, Case S2); tricuspid annular 
plane systolic excursion (TAPSE; see the Supplementary material online, Cases S2, S3, S6); Doppler 
tissue imaging‐derived systolic S′ velocity of the tricuspid annulus (see the Supplementary material 
online, Cases S2–S4); or RV index of myocardial performance (RIMP; see the Supplementary material 
online, Case S2). In addition to TAPSE and S′ velocity, RV global and regional longitudinal shortening 
may be estimated by strain echocardiography.  
 
Assessment of RV ejection fraction based on two‐dimensional echocardiography is not recommended; 
experienced and appropriately equipped centres employ three‐dimensional RV volumes and ejection 
faction with considerable accuracy. 
 
Frequently utilized parameters and reference values of RV dilation, global and segmental function, 
haemodynamic overload, and ventricular interdependence are graphically represented in Figure 
3.42, 44 
Typical ultrasound features of the most common clinical scenarios are shown in Table 3 and in the 
Supplementary material online, Cases S1–S8.42, 44 A comprehensive, more simple evaluation of RV 
function, which takes into account the effect of tidal inflation on RV ejection flow of mechanically 
ventilated patients, has been proposed in the intensive care unit and is part of advanced critical care 
echocardiography.
40
 
  
 
 
 
Figure 3. Graphic representation of echocardiographic parameters in the assessment of right ventricular failure. Ao, aorta; DTI, 
Doppler tissue imaging; EF, ejection fraction; ET, ejection time; FAC, fractional area change; IVC, inferior vena cava; IVCT, 
isovolumic contraction time; IVRT, isovolumic relaxation time; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end‐
diastolic diameter; RA, right atrium; RIMP, right ventricular index of myocardial performance; RV, right ventricle/ventricular; 
RVEDD, right ventricular end‐diastolic diameter; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation. 
 
  
Table 3. Echocardiographic findings in specific clinical settings 
  
Acute pulmonary embolism (Supplementary 
material online, Cases S4, S5)  
Increased RV/LV end‐diastolic diameter ratio 
Regional hypokinesia (McConnell's sign* 
) 
Systole‐diastolic septal shift (D‐shaped left ventricle), paradoxical septal motion 
Peak systolic velocity of TR jet 2.8–3.5 m/s 
Thrombi in proximal pulmonary arteries 
Chronic pulmonary hypertension (acute 
decompensation) 
RV hypertrophy 
RV dilation, spherical shape present in advanced stages 
Systolic/diastolic septal shift, paradoxical septal motion 
Peak systolic velocity of TR jet often >3.5 m/s 
RA enlargement (Supplementary material online, Cases S1, S2) 
Cardiac tamponade (Supplementary material 
online, Case S8)  
Moderate to severe diffuse pericardial effusion (can be compartmentalized after 
surgery) 
RA systolic and RV diastolic collapse 
LA and LV collapse in case of localized post‐surgical tamponade 
Reciprocal respiratory changes (>25%) in RV and LV filling registered by pulsed 
Doppler method at tricuspid and mitral valves 
Normal or slightly elevated PA pressure 
RV myocardial infarction (Supplementary 
material online, Cases S6, S7)  
RV dilation 
Global and regional hypokinesia 
Abnormal septal motion 
Reduced TAPSE 
Reduced S′ velocity 
Congested IVC despite normal or low systolic RV pressure 
Signs of elevated RA and diastolic RV pressure 
Cardiomyopathies DCMP: symmetric pattern of LV and RV dilation and reduced systolic function; 
pulmonary artery pressures are elevated in variable degrees 
ARVC: RV dilation and systolic dysfunction, small free wall aneurysms, 
prominent trabeculation of the right ventricle 
Chagas disease: biventricular apical aneurysms 
Amyloidosis, restrictive infiltrative cardiomyopathy: increased RV wall thickness, 
biatrial dilation 
Takotsubo: global or focal RV apical involvement in 50% of patients 
RV failure after LVAD implantation Visually defined significant systolic RV dysfunction 
RV dilation 
Pronounced septal shift with collapse of LA and LV 
Moderate to severe TR 
  
 
ARVC, arrhythmogenic right ventricular cardiomyopathy; DCMP, dilated cardiomyopathy; IVC, inferior vena cava; LA, left 
atrium; LV, left ventricle; PA, pulmonary artery; RA, right atrial; RV, right ventricular; RVEF, right ventricular ejection fraction; 
TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation. 
* Akinetic mid RV free wall segment with spared apical contractility.  
Invasive haemodynamic assessment with pulmonary artery catheter 
Invasive haemodynamic assessment is recommended in unexplained diagnostic or therapy‐resistant 
cases; it provides continuous, accurate, and valuable information about right and left atrial pressure, 
cardiac output, and pulmonary vascular resistance. In general, invasive monitoring should be used for the 
shortest possible period. 
  
Clinical management 
General overview of managing right ventricular failure 
Effective treatment of RV failure requires a skilled multidisciplinary team
45-47
 to rapidly assess and 
triage the patient to the appropriate environment (Figure 4). The ongoing monitoring varies according to 
the clinical scenario, but its focus is on supporting the RV, managing the consequences of failure, and 
alleviating distressing physical (e.g. breathlessness, pain) and emotional (e.g. anxiety) symptoms (Figure 
4, Table 4).  
 
 
 
Figure 4 Comprehensive care of patients affected by right ventricular failure. Modified from Sztrymf B et al. Acute right heart 
failure in pulmonary hypertension patients. In Gaine S, Naeije R, Peacock A, eds. The Right Heart. Springer Verlag, London, 2013, 
pages 261–275. BNP, B‐type natriuretic peptide; CT, computed tomography; CVP, central venous pressure; ECMO, extracorporeal 
membrane oxygenation; ICU, intensive care unit; IV, intravenous; NO, nitric oxide; PCI, percutaneous coronary intervention; PE, 
pulmonary embolism; RRT, renal replacement therapy; RV, right ventricular.  
  
Table 4. Overview of acute right ventricular (RV) failure treatment 
Strategy Properties and use Caveats 
   
Volume optimization   
Volume loading, saline or ringer lactate, 
>200 mL/15–30 min29 
Consider in patients with decompensated 
RV failure, normal central venous pressure, 
low arterial pressure 
Volume loading can overdistend 
the ventricles, worsen ventricular 
interdependence, and reduce 
cardiac output 
Diuretics   
In patients not receiving oral diuretics the initial 
dose should be 20–40 mg iv; for those on chronic 
diuretic therapy, initial dose of furosemide should 
be at least equivalent to the oral dose 
Intravenous loop diuretics are recommended 
for all patients admitted with 
signs/symptoms of fluid overload to improve 
symptoms 
Can be given either as intermittent boli or 
continuous infusion 
Combination of loop‐diuretic with either 
thiazide‐type diuretic or spironolactone may 
be considered in patients with resistant 
oedema or insufficient symptomatic 
response 
May cause worsening renal 
function and hypokalaemia 
Vasopressors and inotropes   
Noradrenaline, 0.2–1.0 µg/kg.min30 Increases RV inotropy, systemic blood 
pressure, promotes positive ventricular 
interactions, restores coronary perfusion 
gradient 
Excessive vasoconstriction may 
worsen tissue perfusion 
Dobutamine, 2–20 µg/kg.min30 Increases RV inotropy, lowers filling 
pressures 
May aggravate arterial hypotension 
if used alone, without a 
vasopressor, especially if left heart 
failure present 
May trigger or aggravate 
arrhythmias 
Levosimendan, 0.1–0.2 µg/kg.min (6–12 µg/kg 
bolus over 10 min is optional and not 
recommended if SBP <90 mmHg). Infusion can 
be decreased to 0.05 µg/kg.min or increased to 
0.2 µg/kg.min)30 
Combines RV inotropy and pulmonary 
vasodilation; favourably affects right 
ventricular–arterial uncoupling 
May aggravate arterial hypotension 
May trigger or aggravate 
arrhythmias 
Mechanical circulatory support   
ECMO/ECLS Short‐term support, rapid; oxygenator can be 
added 
Complications with use over 
longer periods (>5–10 days) 
Percutaneous catheter mounted micro‐axial 
pumps 
 Limited pump capacity; ECLS 
preferred in severe cardiogenic 
shock or where high pump flow 
required 
Paracorporeal RVADs Appropriate for longer term use (e.g. weeks 
or months); can be combined with 
oxygenators when pulmonary support also 
needed 
 
   
 
ECLS, extracorporeal life support; ECMO, extracorporeal membrane oxygenation; RVAD, right ventricular assist device; SBP, 
systolic blood pressure. 
 
  
Volume optimization 
Patients with RV failure may be preload‐dependent, but volume loading has the potential to 
overdistend the RV and thereby increase wall tension, decrease contractility, aggravate tricuspid 
regurgitation, increase ventricular interdependence, impair left ventricular filling, and ultimately reduce 
systemic cardiac output.
48
 Cautious volume loading guided by central venous pressure monitoring may be 
appropriate if low arterial pressure is combined with the absence of elevated filling pressures.  
 
As RV failure is often caused, associated with, or aggravated by RV volume overload, as mentioned 
above, diuretics are often the first option for most patients with RV failure who present with signs of 
venous congestion along with maintained arterial blood pressure. Volume redistribution in the venous 
system under diuretic treatment can contribute to rapid clinical improvement (Table 4).  
Vasopressor and inotrope treatment 
Vasopressors and/or inotropes are indicated in acute RV failure with haemodynamic instability (Table 
4). Vasopressors such as noradrenaline are primarily indicated to restore blood pressure and improve 
cerebral, coronary, and other organ perfusion. Noradrenaline can improve systemic haemodynamics by 
improvement of ventricular systolic interaction and coronary perfusion without change in pulmonary 
vascular resistance.
49
 Data for vasopressin are lacking in acute RV failure.  
 
Dobutamine, levosimendan and phosphodiesterase III inhibitors improve contractility and increase 
cardiac output. Dobutamine may reduce blood pressure; in that case, a vasopressor, such as noradrenaline, 
is recommended. Levosimendan may favourably affect RV–arterial uncoupling13, 48, 50 by combining RV 
inotropy and pulmonary vasodilation. Phosphodiesterase III receptors are absent in the pulmonary 
vasculature. Thus, phosphodiesterase III inhibitors exert a positive inotrope effect on the right ventricle 
without the deleterious effects on pulmonary vascular resistance that occur with catecholamines. Similar 
to dobutamine, these drugs may aggravate arterial hypotension and should be combined with 
noradrenaline if needed. Levosimendan or phosphodiesterase III inhibitors may be preferentially 
indicated over dobutamine in cardiac patients with pulmonary hypertension caused by left heart disease.  
Mechanical circulatory support 
Acute mechanical circulatory support of the right ventricle may be required in certain clinical 
situations such as RV myocardial infarction (MI), acute PE, following left ventricular assist device 
implantation, or primary graft failure after heart transplantation (Table 4). The most important 
determinant of success is the correct timing of implantation to avoid significant, potentially irreversible 
end‐organ injury. Multiorgan failure is the leading cause of death in unsuccessful cases. Early transfer of 
the patient to an appropriate centre is essential for success. Device selection depends on the anticipated 
duration of mechanical support.  
 
Extracorporeal membrane oxygenation (ECMO) or life support (ECLS) carries the potential for 
increasing use as short‐term mechanical support in the future. It is less expensive than other assist devices 
and can be inserted quickly, even percutaneously.
51
 After 5–10 days, a decision should be made to wean 
the patient and explant the ECMO, or switch to an intermediate or long‐term device, to avoid typical 
ECMO complications (e.g. infections or formation of thrombus around the cannulae, limb hypoperfusion, 
or local infection). Alternatively, percutaneously inserted catheter‐mounted microaxial pumps can be 
used, but these devices may have limited maximum pump capacity.
51
 
  
Right ventricular assist devices (RVADs) can be implanted either surgically
52
 or percutaneously.
53
 
Paracorporeal RVADs can be used for weeks or even months,
54
 but they are only approved for up to 
4 weeks. These devices can easily be combined with oxygenators when needed. In rare cases, if RV 
function is not restored, the insertion of implantable continuous‐flow ventricular assist devices has been 
effective in some reports.
55
 
 
Retrospective reports have shown good results in terms of haemodynamic status and functional 
recovery enabling RVAD explantation in 42–75% of patients.56, 57 Bleeding or thrombus formation are the 
most common complication related to RVADs.
58
 Poor left ventricular function usually predicts worse 
outcomes as isolated RVAD support under these circumstances is insufficient to improve systemic 
perfusion.
56
 
 
Despite case reports of prolonged RV support with an assist device intended for destination therapy,
59 
options for long‐term mechanical circulatory support have been lacking. Thus, cardiac transplant remains 
the ultimate treatment for refractory RV failure.  
Clinical management in specific clinical scenarios 
Pulmonary embolism 
Acute PE is one of the most frequent causes of acute RV failure (see the Supplementary material 
online, Cases 4, 5). Conversely, RV failure is the principal determinant of early mortality in the acute 
phase of PE. Accordingly, and as emphasized in the recently updated (2014) ESC Guidelines on the 
Diagnosis and Management of Acute Pulmonary Embolism,
60 
early detection of clinical, imaging 
(echocardiographic, computed tomographic), and/or laboratory (e.g. natriuretic peptides, cardiac 
troponins) indicators of RV dysfunction and myocardial injury is the cornerstone of a successful risk‐
adjusted therapeutic approach to PE. Based on the contemporary risk classification, ‘high risk’ (formerly 
‘massive’) PE is defined by persistent arterial hypotension or shock caused by overt RV failure, while 
‘intermediate risk’ identifies normotensive patients with a high clinical prognostic score (such as the 
Pulmonary Embolism Severity Index) accompanied by imaging or biochemical markers of RV 
dysfunction, alone (i.e. ‘intermediate‐low risk’) or in combination (i.e. ‘intermediate‐high risk’).60 
 
Reperfusion treatment, mainly systemic (intravenous) thrombolysis, is recommended for patients who 
present with high‐risk PE; in contrast, the haemorrhagic risks of thrombolysis appear to outweigh its 
clinical benefits in patients who are haemodynamically stable at presentation.
61
 Among these latter 
normotensive patients, those with ‘intermediate–high‐risk’ PE should be clinically and haemodynamically 
monitored over the first 2–3 days, as rescue thrombolysis may be necessary if RV dysfunction leads to 
haemodynamic decompensation.  
 
Surgical pulmonary embolectomy is an alternative option for haemodynamically unstable patients 
with high‐risk PE, particularly if thrombolysis is contraindicated or has failed. It may also be considered 
as a rescue procedure in intermediate high‐risk patients in whom haemodynamic decompensation appears 
imminent and the anticipated bleeding risk under systemic fibrinolysis is high.
60
 Catheter‐directed 
techniques for the removal of obstructing thrombi from the main pulmonary arteries have been available 
for several years. ‘Purely interventional’ options such as thrombus fragmentation with pigtail or balloon 
catheter, rheolytic thrombectomy with hydrodynamic catheter devices, suction thrombectomy with 
aspiration catheters and rotational thrombectomy have been reserved for patients with absolute 
contraindications for fibrinolysis. When ‘high‐risk’ patients, or occasionally ‘intermediate‐high‐risk’ 
patients with signs of developing haemodynamic decompensation, have relative contraindications for 
fibrinolysis and an increased bleeding risk, conventional catheter‐directed fibrinolysis through a multi‐
sidehole catheter placed into the thrombus, or pharmaco‐mechanical fibrinolysis, are preferred 
approaches.
62
 
  
Pulmonary hypertension 
Right ventricular function is the major determinant of morbidity and mortality in the pulmonary 
hypertension population, and signs of RV failure frequently dominate the clinical presentation of patients 
with pulmonary arterial hypertension (Group 1) or chronic thromboembolic pulmonary hypertension 
(Group 4; Supplementary material online, Cases S1, S2). Pulmonary hypertension secondary to chronic 
(left) heart (Group 2; Supplementary material online, Case S6) or lung (Group 3) disease may also exhibit 
signs and symptoms of RV failure, but they usually present with clinical features of the underlying 
cardiac or pulmonary disease.  
 
Patients with previously unknown PAH are occasionally seen for the first time in the emergency 
department. If a patient with PAH is seen on an emergency basis, echocardiography is extremely 
important to assess the current status of RV function.
63, 64
 A central venous catheter allows for monitoring 
of SvO2 and central venous pressure in response to therapy. Continuous and complete haemodynamic 
assessment might require the placement of a pulmonary artery catheter, but the expected benefits for 
patient management should be weighed against the risk of complications, including complications with 
vein access, life‐threatening arrhythmias as well as infections and thrombosis.65 
 
Possible triggers for acute RV failure in patients with PAH should be identified.
48, 66-68 
The most 
frequent cause is an infection, and sepsis increases mortality significantly.
67
 Supraventricular arrhythmias 
are common,
69 
and may require electrical cardioversion. Anaemia is also common and may need 
correction. In particular, iron deficiency should trigger a search for potential reasons, and iron 
replacement should be considered; oral iron absorption may be impaired in patients with PAH, therefore, 
intravenous administration may be preferable.
70
 However, the threshold may differ according to the 
clinical situation (e.g., right to left shunting, Eisenmenger syndrome, cyanosis) and there are no studies to 
determine the optimal value for haemoglobin or haematocrit in patients with RV failure. Finally, non‐
adherence to or withdrawal from pulmonary hypertension treatment is another major cause of 
decompensation.  
 
Hypoxia and hypercapnia, as well as acidosis and hypothermia, promote pulmonary vasoconstriction 
and further increase the afterload of the right ventricle. Oxygen therapy should be used to keep an arterial 
oxygen saturation >90%. Non‐invasive ventilation may be indicated in patients with respiratory failure 
and hypercapnia who do not respond to general measures; this may particularly apply to those with 
pulmonary hypertension caused by left heart disease. Positive pressure ventilation should generally be 
avoided because it increases RV afterload and further decreases LV preload. In addition, intubation 
requires sedation that may lead to systemic hypotension
.71
 
 
Diuretics should be the first option for most patients with PAH who present with signs of venous and 
systemic congestion. Renal replacement therapy may be needed in patients with diuretic resistance, but it 
is associated with a dismal prognosis.
72 
Fluid status should be closely monitored by cardiac ultrasound 
and, if comprehensive haemodynamic monitoring is necessary, by pulmonary artery catheter.  
 
Intravenous prostacyclin analogues effectively reduce RV afterload, although care must be taken to 
avoid systemic hypotension.
48, 66-68
 Epoprostenol is the only PAH‐specific drug that has been shown to 
improve survival in World Health Organization (WHO) functional class IV PAH patients.
73 
Inhaled nitric 
oxide
60
 or prostacyclin
70
 may be used in patients who do not tolerate parenteral prostanoids because of 
hypotension. Nitric oxide is frequently used in post cardiac surgery patients. It seems especially 
promising in patients having right ventricular failure after orthotopic heart transplant.
74-76
 
 
Balloon atrio‐septostomy decompresses the right ventricle and, in very specific cases, improves left 
ventricular filling and cardiac output. It may also improve systemic O2 transport despite arterial O2 
desaturation. This is a high‐risk technique and it is not recommended as an emergency procedure because 
the risk of fatal complications is high in unstable patients with high RV filling pressures (right atrial 
pressure >20 mmHg) or low arterial oxygen saturation (<85% at rest on room air).70, 77 In unresponsive 
patients ECMO or RVADs may be necessary as a bridge to recovery or to lung transplant.  
  
Right ventricular infarction 
Acute RV infarction usually occurs in relation to acute inferior wall MI caused by occlusion of the 
proximal right coronary artery (see the Supplementary material online, Cases S6, S7).
78
 It is an 
independent, strongly age‐dependent predictor of short‐term mortality in patients with inferior MI.79, 80 
 
The anatomic occlusion of the infarct‐related artery and functional impairment of the right ventricle 
are poorly correlated. The right ventricle tolerates ischaemic injury better than the left ventricle because it 
has a lower oxygen demand, greater oxygen extraction reserve capability during stress, dual anatomical 
supply from the right and left coronary arteries, relatively homogeneous transmural perfusion across the 
cardiac cycle, and increased propensity to acute collateral development.
81, 82
 
 
Although between 30% and 50% of patients with acute inferior wall MI may have some degree of RV 
involvement, severe hypotension and low cardiac output are uncommon complications in the reperfusion 
era.
80
 Complications such as bradycardia, high‐grade atrioventricular (AV) block, ventricular tachycardia, 
and rupture of the interventricular septum are more frequent in patients with RV infarction.
80, 83, 84
 
 
Treatment of RV infarction includes early myocardial reperfusion, preferably with primary 
percutaneous coronary intervention or, alternatively, with thrombolysis.
79, 85-88 
Complete reperfusion of 
the proximal right coronary artery and the major RV branches may lead to immediate improvement and 
later complete recovery of RV function and to a better clinical outcome. Unlike the left ventricle, the right 
ventricle may remain viable for days after an infarct.
89
 Therefore, late reperfusion is an option that may be 
considered in patients with inferior MI complicated by RV dysfunction.
90-92
 
 
Treatments compromising RV preload (i.e. nitrates, diuretics) may be deleterious and volume 
optimization must be done carefully in order to prevent haemodynamic compromise. In non‐responsive 
patients, inotropic support should be used. In these cases, maintenance of the contribution of the atrial 
kick to maintain cardiac output is also essential. 
 
Avoidance or correction of bradycardia by atropine or aminophylline may become necessary.
93 
High‐
grade AV block usually responds immediately to reperfusion. If it does not, pacing, ideally with AV 
sequential pacing, may be needed.
94, 95
 Reversion of acute atrial fibrillation also improves 
haemodynamics.  
 
Cardiogenic shock is the most severe form of acute MI and acute RV failure as the primary cause of 
cardiogenic shock has been reported in 16% of cases in a recent registry.
96 
Despite younger age, less 
multivessel disease, and better left ventricular ejection fraction, prognosis is no different in cardiogenic 
shock patients with or without acute RV failure.
97
 
Tamponade 
Cardiac tamponade is a clinical syndrome that mimics acute RV failure, and it should be included in 
the differential diagnosis. It is caused by rapid accumulation of fluid (transudate), pus, blood, clots, or gas 
within the pericardial space that compresses the heart, resulting in impaired diastolic filling and reduced 
cardiac output.
98 
The classical clinical picture includes distended jugular veins, an exaggerated inspiratory 
decrease in arterial systolic pressure (paradoxical pulse), arterial hypotension, and diminished heart 
sounds on cardiac auscultation. These signs may be lacking in patients with slowly accumulating 
pericardial fluid. Moreover, typical clinical manifestations maybe absent in the case of localized 
tamponade after cardiac surgery.  
 
Acute cardiac tamponade is usually associated with low blood pressure (<90 mmHg), but blood 
pressure is only slightly reduced in subacute, chronic tamponade. Hypertensive patients may have normal 
to mildly elevated blood pressure concomitant with cardiac tamponade. Fever is a non‐specific sign that 
may be associated with infectious or immune‐mediated pericarditis. 
  
Cardiac tamponade is primarily a clinical diagnosis, and it should be confirmed non‐invasively by 
bedside echocardiography (see the Supplementary material online, Case S8).
99 
Differential diagnosis may 
include acute MI (especially with RV involvement), PE, and aortic dissection in acute‐onset cases. In 
patients with a subacute onset of symptoms, the differential diagnosis should exclude constrictive 
pericarditis (see the Supplementary material online, Case S8), congestive heart failure, and advanced liver 
disease with cirrhosis. Volume resuscitation can be deleterious, except in case of associated 
hypovolaemia. A vasopressor may be needed to correct blood pressure before urgent percutaneous or 
surgical pericardial drainage.
100
 
Acute right ventricular failure in the intensive care setting 
Acute RV failure is frequently encountered in the intensive care unit.
101, 102
 The main cause is ARDS, 
with a reported incidence of RV failure ranging from 25% to 50% depending on severity and mechanical 
ventilation settings.
101, 103, 104
 Most ARDS patients are under positive pressure ventilation. This can 
contribute to an uncoupling between the pulmonary circulation and the RV, predisposing to an inability to 
sustain sufficient blood flow, especially if myocardial contraction is also impaired. Infection as the cause 
of lung injury, plateau pressure, driving pressure, and significant hypercapnia are reported predictors of 
RV failure in ARDS.
102, 105
 Acute RV failure is easily detected by echocardiography,
106 
and 
transoesophageal imaging can be used for monitoring in intubated patients.
101
 A protective ventilation 
strategy with focus on maintaining plateau pressure <27 cmH2O, partial pressure of arterial carbon 
dioxide (PaCO2) <8 kPa (60 mmHg), adapting positive end‐expiratory pressure to RV function, and 
considering prone positioning for PaO2/fraction of inspired oxygen (FiO2) <20 kPa (150 mmHg) has been 
recommended to prevent acute RV failure or ameliorate its complications.
101 
How this strategy may alter 
prognosis remains to be evaluated.  
Valvular disease 
Acute RV dysfunction may be seen in both left‐sided and right‐sided valvular heart disease. Central 
venous pressure may be insufficient to maintain pulmonary arterial flow in the setting of elevated left 
atrial filling pressure that occurs with left‐sided valvular diseases, resulting in RV failure. Right‐sided 
valvular diseases have a significant and independent impact on morbidity and mortality. Tricuspid 
regurgitation is the most frequent right‐sided valvular disease involved in pathogenesis of acute RV 
dysfunction. With functional tricuspid regurgitation being the most common cause, this valvular disorder 
produces adverse haemodynamic consequences on RV function as result of volume overload and RV 
enlargement. An enlarged right ventricle is associated with increased mortality,
107
 and the severity of 
tricuspid regurgitation correlates with worse survival.
108
 Furthermore, moderate or greater tricuspid 
regurgitation is associated with a worse prognosis, even in the absence of ventricular dysfunction or 
pulmonary hypertension.
108
 
 
Right‐sided infective endocarditis accounts for 5–10% of all cases of infective endocarditis.109, 110 It is 
the most prevalent in intravenous drug abusers. Right‐sided endocarditis may occur on native valves, 
prosthetic valves, congenital heart defects, and on implanted devices.
111
 Acute RV dysfunction may arise 
as a consequence of tricuspid valve destruction and severe tricuspid regurgitation with RV volume 
overload and dilatation. Surgery is recommended for patients with right heart failure, severe tricuspid 
regurgitation and a poor response to diuretics, difficult to eradicate infective endocarditis, large 
vegetations, and recurrent emboli.
112
 
Surgery 
In non‐cardiac surgery, perioperative RV failure is most often, although not exclusively, secondary to 
acute pulmonary hypertension (increased afterload). In cardiac surgery, RV failure is also frequently 
caused by volume overload, myocardial ischaemia, pre‐existing RV dysfunction, or arrhythmias.16, 113 
Right ventricular failure in the setting of adult congenital heart disease can be observed in either cardiac 
or non‐cardiac surgery.  
  
Cardiac surgery should be planned anticipating RV failure, and RV function management should 
focus on prevention. Delayed coronary artery bypass graft surgery may be considered for stable patients 
with predominant RV involvement because poor RV function worsens prognosis, but the integrity of 
blood supply to the RV should be restored in patients with RV dysfunction and concurrent ischaemia.
114, 
115 
Patients at risk of acute postoperative RV failure such as those with previous pulmonary hypertension, 
RV dysfunction, severe left ventricular dysfunction, and those with planned long cardiopulmonary bypass 
periods, should be managed by specialized multidisciplinary teams ensuring optimized continued medical 
and surgical care.  
 
Right ventricular function can be jeopardized by several intraoperative factors, such as suboptimal 
myocardial protection, myocardial stunning after long durations on cardiopulmonary bypass, air or 
thromboembolism to the right coronary artery, and mechanical occlusion or kinking of the right coronary 
button or bypass graft. Combined anterograde and retrograde cardioplegia provide superior RV 
myocardial protection.
116
 Avoiding cardiopulmonary bypass may theoretically improve RV myocardial 
protection, although no differences were observed in long‐term follow‐up.117 Liberal transfusion 
strategies should be avoided to prevent increased RV load and negative outcomes.
118 
Maintenance of right 
atrial contraction and AV synchrony was experimentally shown to be crucial preventing deterioration in 
RV failure.
119 
Although LVAD ultimately improves RV function, transient disturbances in loading and 
geometry lead to RV failure that may compromise late outcomes. In addition to demographic and clinical 
parameters (female sex, low body surface area, renal dysfunction), preoperative echocardiographic 
findings (two‐dimensional RV global longitudinal strain <9.6%; three‐dimensional RV ejection fraction 
<20%) have been proposed to assess the risk of RV failure and the potential benefit of planned use of 
biventricular assist devices, but accurate prediction remains challenging.
120-122
 
 
Occasionally, patients may not tolerate sternal closure after cardiac surgery; delayed sternal closure 
for 24 h or more may reduce oedema and extrinsic RV compression.123 
Conclusions 
Acute RV failure is a complex clinical scenario and its appropriate management requires an 
understanding of RV anatomy and mechanics, rapid identification and treatment of underlying causes, 
and knowledge of supportive treatment measures. Many uncertainties remain, and there is a need for 
randomized trials to investigate the efficacy and safety of pharmacological and mechanical interventions 
for the treatment of acute RV failure. 
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